Aliases:This biomarker is also known as:
- cancer/testis antigen 1.6,
- cancer/testis antigen family 1, member 6,
- MAGE-6 antigen,
- MAGE3B antigen,
- Cancer/testis antigen 1.6,
- melanoma antigen family A, 6,
- melanoma-associated antigen 6,
The members of the MAGEA protein family display 50-80% sequence identity among their members. MAGEA proteins are thought to play a role in tumor transformation or aspects of tumor progression. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. Alternative splicing results in multiple transcript variants.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data available.
MAGEA6 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.